ArQule (NASDAQ:ARQL) doses
first patient in the registrational MOSAIC (Miransertib in Overgrowth
Syndromes in Adults and Children) trial of its oral, selective pan-AKT
inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and
PIK3CA-related Overgrowth Spectrum disorders (PROS).
The study will enroll approx. 30-35 patients to
evaluate the objective response to miransertib in patients with PS and
PROS. Same number of patients will be enrolled in 2 other cohorts for
patients under compassionate use or those ineligible to enter the
registrational cohorts.
https://seekingalpha.com/news/3503283-arqule-launches-registrational-study-miransertib-ps-pros
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.